• Cadrenal Therapeutics flagged late-breaking Phase 2 data for CAD-1005 in heparin-induced thrombocytopenia for an oral session at ISTH 2026.
• Results will be presented July 12, 2026 in Paris; the trial is described as the first randomized, blinded, placebo-controlled study in HIT.
• The readout supports CAD-1005 as Phase 3-ready, positioning it as a potential differentiated option targeting HIT’s immune-driven mechanism.
• The company framed HIT as a peak $2 billion annual revenue opportunity, highlighting the program’s commercial importance.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cadrenal Therapeutics Inc. published the original content used to generate this news brief on June 24, 2026, and is solely responsible for the information contained therein.